Lawsuit filed for Investors who lost money with shares of Inspire Medical Systems, Inc. (NYSE: INSP)

An investor, who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP), filed a lawsuit over alleged violations of Federal Securities Laws by Inspire Medical Systems, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP) have certain options and for certain investors are short and strict deadlines running. Deadline: January 5, 2026. NYSE: INSP investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Golden Valley, MN based Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally.
Inspire Medical Systems, Inc. (NYSE: INSP) develops and manufactures an implantable medical device called "Inspire" to treat obstructive sleep apnea. The latest version of the Company's device, Inspire V, uses an implanted sensor and neurostimulator designed to improve respiration during sleep.

Inspire Medical Systems, Inc. (NYSE: INSP) reported that its annual Total Revenue rose from $624.79 million in 2023 to $802.8 million in 2024 and that its Net Loss of $21.15 million in 2023 turned into a Net Income of $53.5 million in 2024.

Then on August 4, 2025 Inspire Medical Systems, Inc. revealed that the Inspire V launch was facing an "elongated timeframe" because, among other issues, "many centers did not complete the training, contracting and onboarding criteria required prior to the purchase and implant of Inspire V." That same day, Inspire Medical Systems, Inc. admitted that although Inspire V's CPT code has been approved for Medicare patients, "software updates for claims submissions and processing did not take effect until July 1," which meant that "implanting centers would not be able to bill for those procedures until July 1." As a result, many treatment centers simply chose to continue treating with Inspire IV. Finally, Defendants revealed that the Inspire V rollout was plagued by poor demand resulting from excess inventory, and the Company reduced its 2025 earnings guidance by more than 80%.

Shares of Inspire Medical Systems, Inc. (NYSE: INSP) declined from $218.52 per share on September 23, 2024, to as low as $70.77 per share on October 01, 2025.

the plaintiff claims that between August 6, 2024 through August 4, 2025, the Defendants misrepresented and failed to disclose key facts about Inspire V, including the actual market demand for the device and whether the company had taken the steps necessary to successfully launch it, that the Defendants issued a series of materially false and misleading statements that led investors to believe demand for Inspire V was strong and that Company had taken the necessary steps for a successful launch.

Those who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.